Loading...
Docoh

Sierra Oncology (SRRA)

Utility
Methods of Treatment of Cancer Comprising CDC7 Inhibitors
23 Dec 21
Herein disclosed are methods of treatment administering SRA141 as a monotherapy or in a combination therapy useful for inhibiting the growth of tumors such as those in patients with cancer.
Christian Andrew Hassig, Ryan James Hansen, Snezana Milutinovic, Bryan William Strouse
Filed: 28 Aug 19
Utility
Platelet Count-Agnostic Methods of Treating Myelofibrosis
30 Sep 21
Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy.
Barbara Jane Klencke, Gregg David Smith, Rafe Michael Joseph Donahue
Filed: 21 Aug 19
Utility
CHK1 (SRA737)/PARPI Combination Methods of Inhibiting Tumor Growth
18 Mar 21
Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer.
Christian Andrew HASSIG, Bryan William STROUSE, Ryan James HANSEN, Kenna Lynn ANDERES
Filed: 10 Apr 18
Utility
Methods of Treatment of Cancer Comprising CHK1 Inhibitors
23 Dec 20
Herein disclosed are methods of treatment administering SRA737 as a monotherapy or in a combination therapy useful for treating patients with cancer.
Christian Andrew HASSIG, Bryan William STROUSE, Ryan James HANSEN, Kenna Lynn ANDERES, Snezana MILUTINOVIC, Angie J. YOU, Barbara KLENCKE, Mark KOWALSKI
Filed: 25 Feb 19
Reissue
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
26 Oct 20
The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
Filed: 17 Oct 18
Utility
Biomarkers and Patient Selection Strategies
20 May 20
Herein disclosed are methods for treatment of cancer and methods for patient selection for administration of cancer treatment regimens comprising inhibitors of checkpoint kinase 1 (Chk1).
Christian Andrew HASSIG, Bryan William STROUSE, Ryan James HANSEN, Angie J. YOU
Filed: 31 May 18
  • 1
Patents are sorted by USPTO publication date, most recent first